Physician profile
Alejandro Lorenzana
NPI 1346326485
$9,862.10
in general payments reported to CMS, 2019-2025
38 companies · $2,858 in 2025
The $2,858 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $384 · 2021: $1,131 · 2022: $834 · 2023: $1,857 · 2024: $2,053 · 2025: $2,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,735 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,734.56 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,672.60 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,181.19 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $683.90 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $533.90 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $525.36 | 2020-2025 | Glassia, Cuvitru |
| Pfizer INC. | $509.36 | 2019-2025 | |
| Amgen INC. | $467.90 | 2022-2025 | Tezspire, Tavneos |
| Grifols USA, LLC | $443.98 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $442.05 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $237.25 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $201.46 | 2019-2023 | Yupelri |
| Philips North America LLC | $183.43 | 2020-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Baxter Healthcare | $164.10 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Sunovion Pharmaceuticals INC. | $149.70 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $148.51 | 2019-2025 | Opsumit, Opsynvi |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $144.00 | 2021-2022 | |
| United Therapeutics Corporation | $134.86 | 2023-2025 | Tyvaso, Tyvaso |
| Mallinckrodt Hospital Products INC. | $133.28 | 2020-2025 | Acthar |
| Genentech USA, INC. | $101.84 | 2019-2024 | Xolair |
| Janssen Pharmaceuticals, INC | $98.04 | 2019-2022 | |
| Inogen, INC. | $87.22 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Merck Sharp & Dohme LLC | $81.00 | 2022-2025 | Zerbaxa |
| Verona Pharma, INC. | $80.50 | 2025 | Ohtuvayre |
| Abbvie INC. | $69.98 | 2022-2024 | |
| Insmed, INC. | $63.11 | 2023-2025 | Arikayce |
| E.R. Squibb & Sons, L.L.C. | $46.64 | 2019-2024 | Eliquis |
| Resmed Corp | $37.12 | 2024 | |
| Paratek Pharmaceuticals, INC. | $32.84 | 2022-2023 | Nuzyra |
| Alexion Pharmaceuticals, INC. | $29.61 | 2020-2021 | |
| Lilly USA, LLC | $29.17 | 2025 | Zepbound |
| Inspire Medical Systems, INC. | $28.17 | 2023 | Inspire |
| Electromed, INC. | $24.95 | 2023 | Smartvest |
| Liquidia Technologies, INC. | $21.46 | 2025 | Yutrepia |
| Circassia INC. | $16.25 | 2019 | |
| Sanofi Pasteur INC. | $15.72 | 2023 | |
| Viatris Specialty LLC | $15.52 | 2025 | Yupelri |
| Bio Products Laboratory USA, INC. | $13.79 | 2022 | |
| Shire North American Group INC | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Lorenzana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.